S
Suzanne Oparil
Researcher at University of Alabama at Birmingham
Publications - 941
Citations - 122414
Suzanne Oparil is an academic researcher from University of Alabama at Birmingham. The author has contributed to research in topics: Blood pressure & Angiotensin II. The author has an hindex of 106, co-authored 885 publications receiving 113983 citations. Previous affiliations of Suzanne Oparil include Michigan State University & Oregon Health & Science University.
Papers
More filters
Journal ArticleDOI
Catheter‐Based Renal Denervation for Resistant Hypertension: Rationale and Design of the SYMPLICITY HTN‐3 Trial
David E. Kandzari,Deepak L. Bhatt,Paul A. Sobotka,William W. O'Neill,Murray D. Esler,John M. Flack,Barry T. Katzen,Martin B. Leon,Joseph M. Massaro,Manuela Negoita,Suzanne Oparil,Krishna J. Rocha-Singh,Craig A. Straley,Raymond R. Townsend,George L. Bakris +14 more
TL;DR: The SYMPLICITY HTN‐3 Trial is a pivotal study designed as a prospective, randomized, masked procedure, single‐blind trial evaluating the safety and effectiveness of catheter‐based bilateral renal denervation for the treatment of uncontrolled hypertension despite compliance with at least 3 antihypertensive medications of different classes at maximal tolerable doses.
Journal ArticleDOI
Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women
Lori Mosca,Lawrence J. Appel,Emelia J. Benjamin,Kathy Berra,Nisha Chandra-Strobos,Rosalind P. Fabunmi,Deborah Grady,Constance K. Haan,Sharonne N. Hayes,Debra R. Judelson,Nora L. Keenan,Patrick McBride,Suzanne Oparil,Pamela Ouyang,Mehmet C. Oz,Michael E. Mendelsohn,Richard C. Pasternak,Vivian W. Pinn,Rose Marie Robertson,Karin Schenck-Gustafsson,Cathy A. Sila,Sidney C. Smith,George Sopko,Anne L. Taylor,Brian W. Walsh,Nanette K. Wenger,Christine L. Williams +26 more
TL;DR: In the wake of the reports of the Women's Health Initiative and the Heart and Estrogen/Progestin Replacement Study (HERS), which unexpectedly showed that combination hormone therapy was associated with adverse CVD effects, there is a heightened need to critically review and document strategies to prevent CVD in women.
Journal ArticleDOI
Characteristics of 9194 Patients With Left Ventricular Hypertrophy The LIFE Study
Björn Dahlöf,RB Devereux,Stevo Julius,S E Kjeldsen,Gareth Beevers,U de Faire,Frej Fyhrquist,Thomas Hedner,H Ibsen,Krister Kristianson,Ole Lederballe-Pedersen,L. H. Lindholm,Markku S. Nieminen,Per Omvik,Suzanne Oparil,H Wedel +15 more
TL;DR: The Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study as discussed by the authors is a double-blind, prospective, parallel group study designed to compare the effects of losartan with those of the beta-blocker atenolol on the reduction of cardiovascular morbidity and mortality.
Journal ArticleDOI
Effects of Intensive BP Control in CKD
Alfred K. Cheung,Mahboob Rahman,Mahboob Rahman,David M. Reboussin,Timothy E. Craven,Tom Greene,Paul L. Kimmel,William C. Cushman,Amret T. Hawfield,Karen C. Johnson,Cora E. Lewis,Suzanne Oparil,Michael V. Rocco,Kaycee M. Sink,Paul K. Whelton,Jackson T. Wright,Jan Basile,Jan Basile,Srinivasan Beddhu,Udayan Bhatt,Tara I. Chang,Glenn M. Chertow,Michel Chonchol,Barry I. Freedman,William E. Haley,Joachim H. Ix,Lois A. Katz,Lois A. Katz,Anthony A. Killeen,Vasilios Papademetriou,Ana C. Ricardo,Karen S. Servilla,Barry M. Wall,Barry M. Wall,Dawn F. Wolfgram,Jerry Yee +35 more
TL;DR: Among patients with CKD and hypertension without diabetes, targeting an SBP<120 mm Hg compared with <140mm Hg reduced rates of major cardiovascular events and all-cause death without evidence of effect modifications by CKD or deleterious effect on the main kidney outcome.
Journal ArticleDOI
Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats
TL;DR: The hypothesis that endogenous endothelin-1 plays a major role in hypoxic pulmonary vasoconstriction and/or hypertension, right heart hypertrophy, and pulmonary vascular remodeling is supported and it is suggested that endothelins-receptor blockade may be useful in the treatment of hypoxia-induced pulmonary hypertension humans.